Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063124 · ClinicalTrials.gov registry record · Phase 1
Senolytic Therapy to Modulate Progression of Alzheimer's Disease
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04063124 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 5 participants.
The verdict
NCT04063124, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) \[D+Q\], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans with other chronic illnesses and in Alzheimer's mice models. The study team want to know if this combination of medications will reach the brain in order to evaluate if this intervention may be effective for treating AD symptoms in future studies. This is also known as a "proof of concept" study.
Interventions
- DRUG Dasatinib + Quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04063124
The ClinicalTrials.gov registry entry for NCT04063124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib + Quercetin is the first listed.
NCT04063124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04063124 about?
NCT04063124 is a clinical study titled "Senolytic Therapy to Modulate Progression of Alzheimer's Disease". The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) \[D+Q\], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells i...
What is the current status of trial NCT04063124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-02-14. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04063124?
The interventions under investigation include: Dasatinib + Quercetin (DRUG).
Who is sponsoring clinical trial NCT04063124?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.